1. Volume 142, Issue 2, Pages 257-265.e3 (February 2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to- Severe Ulcerative Colitis 
William J. Sandborn, Gert van Assche, Walter Reinisch, Jean–Frederic Colombel, Geert D'Haens, Douglas C. Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B. Thakkar 
Gastroenterology 
Volume 142, Issue 2, Pages e3 (February 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1
(A) Proportion of patients with clinical remission at week 8 and week 52. Proportion of patients with (B) clinical response and (C) mucosal healing at week 8 and week 52. (D) Proportion of patients achieving remission per partial mayo score over time. (E) Corticosteroid discontinuation by visit among baseline corticosteroid users. Intent-to-treat population; nonresponder imputation method. *P < .05; **P < .005 based on Cochran–Mantel–Haenszel test.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Supplementary Figure 1
Patient flow. OL, open-label; eow, every other week. aSites were noncompliant with good clinical practices and protocol requirements.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

4. Supplementary Figure 2
(A) Summary of odds ratios for the proportion of patients achieving clinical remission at week 8 for adalimumab vs placebo by subgroup. (B) Summary of odds ratios for the proportion of patients achieving clinical remission at week 52 for adalimumab vs placebo by subgroup. aMedian age, 39 years. bOdds ratio could not be calculated for “other” race category. cOdds ratio could not be calculated for “≥64” age category. dOdds ratio could not be calculated for “current user” prior tobacco use category.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

5. Supplementary Figure 2
(A) Summary of odds ratios for the proportion of patients achieving clinical remission at week 8 for adalimumab vs placebo by subgroup. (B) Summary of odds ratios for the proportion of patients achieving clinical remission at week 52 for adalimumab vs placebo by subgroup. aMedian age, 39 years. bOdds ratio could not be calculated for “other” race category. cOdds ratio could not be calculated for “≥64” age category. dOdds ratio could not be calculated for “current user” prior tobacco use category.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions